BIAF
bioAffinity Technologies, Inc.
There isn't enough reported data to score BIAF yet.
BIAF Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
BIAF's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
BIAF PE Valuation
BIAF has no meaningful PE right now: it lost money over the past year.
BIAF Forward outlook
There aren't enough analyst estimates for BIAF to show an outlook.
BIAF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$81.49 | +$228.11 |
| Q2 2026 | -$146.70 | +$163.80 |
| Q1 2026 | -$213.60 | +$105.90 |
| Q4 2025 | -$273.45 | +$64.05 |
| Q3 2025 | -$309.60 | +$59.40 |
| Q2 2025 | -$310.50 | +$103.50 |
| Q1 2025 | -$319.50 | +$99.00 |
| Q4 2024 | -$337.50 | +$72.00 |
BIAF is still losing money, but far less than before: $81.49 per share over the past year, against $1,702.04 at its worst in late 2022.
BIAF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -26% |
| Q2 2026 | $1.5M | +19% |
| Q1 2026 | $1.4M | -27% |
| Q4 2025 | $1.6M | -28% |
| Q3 2025 | $1.4M | -38% |
| Q2 2025 | $1.3M | -47% |
| Q1 2025 | $1.9M | -23% |
| Q4 2024 | $2.2M | -71% |
BIAF's revenue has slid since its 2023 peak: $1M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -328% | -169 points |
| Q2 2026 | -221% | -23 points |
| Q1 2026 | -268% | -126 points |
| Q4 2025 | -197% | -64 points |
| Q3 2025 | -159% | -75 points |
| Q2 2025 | -198% | -111 points |
| Q1 2025 | -142% | -61 points |
| Q4 2024 | -133% | -103 points |
BIAF's operating margin was −328% last quarter, down 169 points from the same quarter a year ago.
BIAF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.9M | -$1.5M |
| Q2 2026 | -$3.3M | -$630.4K |
| Q1 2026 | -$3.2M | -$1.5M |
| Q4 2025 | -$2.6M | -$882.4K |
| Q3 2025 | -$2.5M | -$758K |
| Q2 2025 | -$2.7M | -$1.1M |
| Q1 2025 | -$1.7M | +$694.8K |
| Q4 2024 | -$1.7M | -$74.3K |
BIAF has burned cash in almost every quarter: −$13M over the past year, against −$9M the year before.
BIAF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +157% | +548K shares |
| 1 year | +1579% | +843K shares |
| 3 years | +9494% | +887K shares |
BIAF has 896,271 diluted shares, up 1579% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
BIAF Net Leverage
BIAF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BIAF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 1.0 | Oversold |
BIAF's weekly RSI is 34 (neutral) and its Stochastic is 1 (oversold).
BIAF PE vs Healthcare Sector
BIAF has no meaningful PE right now: it lost money over the past year.
BIAF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.15 | 44% below |
| 20 week MA | $7.21 | 68% below |
| 50 week MA | $18.6 | 87% below |
| 100 week MA | $94.0 | 98% below |
| 200 week MA | $449.1 | 99% below |
BIAF is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
BIAF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $3,172.5 | $832.5 | -74% |
| 2023 | $832.5 | $661.5 | -21% |
| 2024 | $661.5 | $400.4 | -39% |
| 2025 | $400.4 | $17.6 | -96% |
| 2026 YTD | $17.6 | $2.34 | -87% |
BIAF has finished every year since 2022 lower, and it's down 87% so far in 2026.